A couple of weeks ago, we brought you “The ‘Identity Of Who Is Propping Up Bitcoin’ Is Revealed!‘” The exclamation point in the title was obviously sarcasm, something at least one commentator didn’t seem to immediately grasp, but you know, nuance isn’t for everyone. That post contained some excerpts from a Deutsche Bank note that…
Here are the currencies and commodities that do well or poorly in January, historically. Statistics include how often the prices rise or fall, and by how much, on average. Statistics are based on monthly opening and closings prices, and do no reflect overall volatility that occurs during the month. Commodity statistics are based on a…
With just a few hours left for the year to end, it can be said that 2017 turned out to be a pretty good year for the biotech sector. The sector had been struggling due to several issues including the drug pricing controversy, mixed results, slower-than-expected new product launches, increasing competition and pipeline setbacks. However,…
The XRP price has soared over the weekend to overtake Ethereum as the second largest cryptocurrency in the world, thanks to three of the credit card majors from Japan and other big players in the financial markets. As the world moves in to greet the New Year, 2018, the last trading day of 2017 saw the market cap of…
Following the ideas of Keynes and Friedman, most mainstream economists associate economic growth with increases in the demand for goods and services. Both Keynes and Friedman felt that The Great Depression of the 1930’s was due to an insufficiency of aggregate demand and thus the way to fix the problem is to boost aggregate demand….
USD/CAD broke below 1.2623 support, indicating that the upside movement from 1.2061 had completed at 1.2916 already. A deeper decline to test 1.2433 support could be seen next week. A breakdown below this level could trigger further downside movement towards the 1.2061 previous low. Near term resistance is at 1.2700, only a break above this…
The pharma/biotech industry was plagued by drug pricing issues last year. However, it bounced back and made a considerable headway this year, courtesy of a slew of FDA approvals. Particularly, large-cap players in the industry raked in stellar returns, up 16.5%, not to forget that the same space posted a decline of 5.2% in the…
The last Housing Market Review covered data reported in November, 2017 for October, 2017. At the time, the iShares U.S. Home Construction ETF (ITB) traded at a 10+ year high with the angst of tax reform left far behind in the rear view mirror. The day after my post, Toll Brothers (TOL) reported earnings that disappointed the market. The…
It goes without saying that one of the tragedies of 2017 was the relegation of reality to the backburner of public discourse. I’m not much on the notion that there is an objective distinction between “right” and “wrong” (“right” and “wrong” are almost always subjective). On a personal note, I once publicly castigated a former…
The goal of most investors is to either: Maximize returns given a fixed level of risk Minimize risk given a particularly level of desired returns Perhaps the best metric for analyzing both risk and return is the Sharpe Ratio. With that in mind, we’ve compiled a list of all stocks in the S&P 500 sorted by 5-Year…
